Hopital Saint Eloi — Clinical Trial Site

37 Registered trials

10 Currently recruiting

Organisation

Hopital Saint Eloi

Location

Montpellier Cedex 5, France

Identifier

ORG-100028390

Address

80 Avenue Augustin Fliche, 34295, France

Departments

#1104: Dermatology
2305: Oncologie médicale
3107: Service de Médecine Vasculaire
34
CHU Montpellier - Hôpital Saint Eloi
Clinical Haematology
Département d'Hématologie clinique
Département de dermatologie
Department of Clinical Hematology
HEMATOLOGIE CLINIQUE
Hematology
Hematology Department
Hépato-gastro-entérologie
hepato-gastro-enterology
Hepato-gastroenterology and Liver transplantation unit
Hepatogastroenterology
Hôpital Saint Eloi Département d’Hématologie Clinique
Medical Oncology
n/a
Service d'Oncologie Médicale
Service d’Hématologie clinique
Service d’Oncologie Médicale
Service de Cardiologie - Soins intensifs (USIC)
Service Hépato-gastro- entérologie
Service Hépato-gastro-entérologie
Service: Hépato-gastro-entérologie A

Clinical trials at this site (37)

Search interface

ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Not authorised

2022-500535-36-00 Moderately to severely active ulcerative colitis 5
ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised

2022-500537-84-00 Moderately to severely active ulcerative colitis 5
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Pati… Not authorised

2022-502043-35-00 Advanced Biliary Tract Cancers 5
A Phase 1/2a Study of UCART20x22 in B-Cell Non-Hodgkin Lymphoma [NatHaLi-01] Recruiting

2022-501607-27-00 Relapsed or refractory B-cell Non-Hodgkin lymphoma 7 2026-01-06
HyperChrono Recruiting

2023-506663-33-00 IDIOPATHIC HYPERSOMNIA 4 2024-09-07
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Untreated FLIPI 2-5 Follicular Lymphoma 5 2024-06-03
Study of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting

2022-501119-14-01 Ulcerative Colitis 4 2024-04-16
FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab … Recruiting

2022-501554-11-00 Patients with previously untreated Richter’s syndrome ( 4 2024-03-21
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrho… Recruiting

2023-505141-48-00 Fibrosis 5 2024-03-07
Alpelisib for the treatment of lymphatic malformations associated with a PIK3CA mutation Recruiting

2023-504146-60-00 lymphatic malformations associated with PIK3CA mutation 10 2024-02-07
A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory… Recruiting

2023-503206-37-00 Mantle Cell Lymphoma (MCL) 5 2023-11-20
MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient… Recruiting

2022-501810-77-00 Relapsed or Refractory Marginal Zone Lymphoma 5 2023-09-01
Interest of systematic treatment with PPI after endoscopic myotomy compared to PPI treatment in case of symptoms in prevention of gastroesop… Recruiting

2022-500218-25-01 esophageal achalasia 6 2023-06-01
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy,… Ended

2023-505739-12-01 Chronic Inducible Urticaria (CINDU) 5 2024-09-30
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Pati… Ended

2022-502043-35-01 Advanced Biliary Tract Cancers 5 2024-04-24
Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC): Evaluation of the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Co… Ended

2022-502948-13-00 Hepatocellular Carcinoma 4 2024-03-01
A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com… Ended

2022-501576-25-00 Melanoma 5 2023-07-07
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL Ended

2023-504187-42-00 Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leuk 1 2022-09-12
A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease Ended

2022-501645-70-00 Crohns Disease 5 2020-11-25
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Acute Myeloid Leukemia (AML) 4 2019-12-20
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto… Ended

2023-504932-16-00 Muscle Invasive Bladder Cancer 5 2019-06-04
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Acute myeloid leukemia 5 2019-03-01
LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended

2023-507657-15-00 Ulcerative Colitis 5 2018-09-13
Long Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis. Ended

2023-505699-31-00 Ulcerative Colitis 5 2017-01-02